Latest Breaking News On - Armata pharmaceuticals inc - Page 5 : comparemela.com

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesFrance generalPierre kymeDeborah birxDeborahl birxJoyce allairePrnewswire armata pharmaceuticals incArmata pharmaceuticals incDefense health agencyTechnology enterprise consortiumWarfighter medical research programUs department of defenseLifesci advisorsRecent developmentsInnoviva boardChief executive

ARMP Stock Price | Armata Pharmaceuticals Inc Stock Quote (U S : NYSE American)

ARMP | Complete Armata Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Los angelesArmata pharmaceuticals incArmata pharmaceuticalsRmp analyst estimatesRmp earnings estimatesRmp share estimatesRmp analyst recommendationsRmp ratingsRmata pharmaceuticals inc analyst estimatesRmata pharmaceuticals inc earnings estimatesRmata pharmaceuticals inc analyst recommendationsRmata pharmaceuticals inc analyst ratings

Armata Pharmaceuticals, Inc (NYSEAMERICAN:ARMP) Short Interest Up 688 3% in July

Armata Pharmaceuticals, Inc (NYSEAMERICAN:ARMP) Short Interest Up 688 3% in July
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Armata pharmaceuticals incNews ratings for armata pharmaceuticals dailyArmata pharmaceuticals stock performanceNorthern trust corpRenaissance technologiesVanguard group incInstitutional investors weigh in on armata pharmaceuticalsArmata pharmaceuticalsGet free reportTrust corpStreet groupVanguard groupArmata pharmaceuticals daily

Armata Pharmaceuticals (ARMP) to Release Earnings on Wednesday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) is scheduled to issue its quarterly earnings data on Wednesday, August 9th. Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The […]

Earnings history for armata pharmaceuticalsArmata pharmaceuticals incArmata pharmaceuticalsInstitutional investors weigh in on armata pharmaceuticalsNews ratings for armata pharmaceuticals dailyVanguard group incRenaissance technologiesArmata pharmaceuticals stock performanceNorthern trust corpGet free reportTrust corpJane street groupArmata pharmaceuticals dailyNyseamerican armp

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of.

Acinetobacter baumannii calcoaceticusPavel raifeldDeborah birxSecurities exchangeExchange commissionGlaxo group limitedTheravance respiratory companyJolla pharmaceutical companyInnoviva incArmata pharmaceuticals incChief executive officerInnoviva strategic opportunitiesArmata pharmaceuticalsInnoviva boardChief executiveInnoviva specialty therapeutics